Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibody–drug conjugates: Recent advances in payloads
Zhijia Wang, Hanxuan Li, Lantu Gou, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 10, pp. 4025-4059
Open Access | Times Cited: 94

Showing 1-25 of 94 citing articles:

Exploring treatment options in cancer: Tumor treatment strategies
Beilei Liu, Hongyu Zhou, Licheng Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 155
A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
Federico Riccardi, Michele Dal Bo, Paolo Macor, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 68
Bispecific antibody drug conjugates: Making 1+1>2
Yilin Gu, Zhijia Wang, Yuxi Wang
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 5, pp. 1965-1986
Open Access | Times Cited: 30
Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs
Virginia Metrangolo, Lars H. Engelholm
Cancers (2024) Vol. 16, Iss. 2, pp. 447-447
Open Access | Times Cited: 25
Expanding the horizons of targeted protein degradation: A non-small molecule perspective
Xiaowei Huang, Fengbo Wu, Jing Ye, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2402-2427
Open Access | Times Cited: 16
Antibody-Drug Conjugates: A promising breakthrough in cancer therapy
Swapnali Parit, Ajit Manchare, Amol D. Gholap, et al.
International Journal of Pharmaceutics (2024) Vol. 659, pp. 124211-124211
Closed Access | Times Cited: 15
Single-domain antibodies as therapeutics for solid tumor treatment
Mingkai Wang, Tianlei Ying, Yanling Wu
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 7, pp. 2854-2868
Open Access | Times Cited: 11
Directly targeting BAX for drug discovery: Therapeutic opportunities and challenges
Zhenwei Zhang, Linghui Hou, Dan Liu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2378-2401
Open Access | Times Cited: 9
Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody–Drug Conjugates
Tomohiro Watanabe, Naoko Arashida, Tomohiro Fujii, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 20, pp. 18124-18138
Open Access | Times Cited: 9
EGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells
Bita Jafary, Mostafa Akbarzadeh-Khiavi, Hamed Farzi-Khajeh, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma
Ali Al Sbihi, Maryam Alasfour, Georgios Pongas
Cancers (2024) Vol. 16, Iss. 4, pp. 827-827
Open Access | Times Cited: 7
Comprehensive review on the elaboration of payloads derived from natural products for antibody-drug conjugates
Nan Lu, Jiaqi Wu, Mengwei Tian, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116233-116233
Closed Access | Times Cited: 7
Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?
Baochen Zhang, Mo Wang, Li Sun, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 14, pp. 11469-11487
Closed Access | Times Cited: 7
A novel shark VNAR antibody-based immunotoxin targeting TROP-2 for cancer therapy
Xiaozhi Xi, Yanqing Wang, Guiqi An, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 11, pp. 4806-4818
Open Access | Times Cited: 7
Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research
Youngbo Choi, Y. Choi, Surin Hong
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 221-221
Open Access | Times Cited: 6
Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy
Chi Hun Song, Minchan Jeong, H. In, et al.
Antibodies (2023) Vol. 12, Iss. 4, pp. 72-72
Open Access | Times Cited: 14
Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry
Tomohiro Fujii, Yutaka Matsuda
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 11, pp. 1053-1065
Closed Access | Times Cited: 14
Polyethylene Glycol–Based Polymer-Drug Conjugates: Novel Design and Synthesis Strategies for Enhanced Therapeutic Efficacy and Targeted Drug Delivery
Vinay Sagar Verma, Aakansha Pandey, Arvind Kumar Jha, et al.
Applied Biochemistry and Biotechnology (2024) Vol. 196, Iss. 10, pp. 7325-7361
Open Access | Times Cited: 5
Antibody–Drug Conjugates—Evolution and Perspectives
Adriana Aurelia Chiș, Carmen Maximiliana Dobrea, Anca Maria Arseniu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 6969-6969
Open Access | Times Cited: 5
Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development
Whi‐An Kwon, Seo Yeon Lee, Tae Cheon Jeong, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2420-2420
Open Access | Times Cited: 5
Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads
Giovanni Tonon, Flavio Rizzolio, Fabiano Visentin, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 8651-8651
Open Access | Times Cited: 5
Natural-source payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions
Cuiping Li, Kourong Shi, Siyuan Zhao, et al.
Pharmacological Research (2024) Vol. 207, pp. 107341-107341
Open Access | Times Cited: 5
Resistance to antibody–drug conjugates: A review
Sijia Li, Xinyu Zhao, Kai Fu, et al.
Acta Pharmaceutica Sinica B (2025) Vol. 15, Iss. 2, pp. 737-756
Open Access
Design and Synthesis of Isatin Derivative Payloaded Peptide-Drug Conjugate as Tubulin Inhibitor against Colorectal Cancer
Guoyang Sun, Zhao‐Yang Wang, Yanping Li, et al.
European Journal of Medicinal Chemistry (2025) Vol. 285, pp. 117276-117276
Closed Access
Targeting the activated allosteric conformation of the endothelin receptor B in melanoma with an antibody-drug conjugate: mechanisms and therapeutic efficacy
Amaury Herbet, Marie Hautière, Frédéric Jean‐Alphonse, et al.
BJC Reports (2025) Vol. 3, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top